

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-31. (Cancelled)

32. (Currently Amended) ~~The~~A method of ~~Claim 28 further~~for inhibiting growth of a cell that overexpresses ErbB2, the method comprising:

- a) exposing ~~a~~the cell to an isolated first antibody that binds SEQ ID NO:2 of ErbB2, wherein said binding induces apoptosis of said cell; and
- b) subsequently exposing the cell to a second anti-ErbB2 antibody that does not bind binds ErbB2 at an epitope other than 7C2/7F3 (SEQ ID NO:2) of ErbB2.

33. (Currently Amended) The method of Claim ~~28-32~~32, ~~further comprising exposing the cell to a~~wherein said second antibody~~that binds ErbB2 and~~ inhibits growth of SKBR3 cells in cell culture by 50-100%.

34. (Currently Amended) The method of Claim ~~33-32~~32, wherein the cell is exposed to the first antibody before the cell is exposed to the second antibody.

35. (Currently Amended) The method of Claim ~~33-32~~32, wherein the second antibody binds epitope 4D5 (SEQ ID NO:4) on ErbB2.

36. (Currently Amended) The method of Claim ~~33-32~~32, wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.

37-38. (Cancelled)

39. (Currently Amended) The method of Claim ~~28~~32, further comprising exposing the cell to radiation.

40-42. (Cancelled)

43. (Currently Amended) The method of Claim ~~42~~32, wherein the cell is a cancer cell.

44-50. (Cancelled)

51. (Currently Amended) The method of Claim ~~28~~32 wherein the antibody is humanized 7C2.

52-65. (Cancelled)